Hinnah Campwala (left) is a Principal Scientist in the Cell Biology Development Group at Sartorius BioAnalytical Instruments (Michigan, USA). With a background in drug discovery and immune cell ...

Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...

In recent years, there has been an increase in the number of registered clinical trials evaluating recombinant adeno-associated virus (AAV)-based gene therapies, in part due to AAV’s ability to ...

In recent years, non-viral methods for cell engineering have emerged as promising alternatives to viral transduction. Amongst the virus-free technologies, electroporation is considered the gold ...

No currently available treatment is able to generate new contractile tissue or significantly improve cardiac function after myocardial infarction (MI), a leading cause of morbidity and mortality ...

In this interview, News Med talks to Hinnah Campwala about the pivotal role of transfection in modern research and drug discovery. Transfection is a tool that sees widespread use across a diverse ...

That’s gene editing. On paper, it is merely the rearrangement of letters. However, the road to editing genes in hopes of a therapeutic benefit is difficult to travel. Additionally, researchers want ...

Polymer-based gene delivery systems represent a promising class of non-viral vectors, offering significant advantages in safety, structural versatility, biodegradability, and the potential for ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently delivers genetic material into human immune cells. The platform, called ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and ...